Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative-Reference-Cited by-同舟云学术

Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative

Published:2008-10 Issue:10 Volume:83 Page:1131-1135
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Gertz Morie A.,Ansell Stephen M.,Dingli David,Dispenzieri Angela,Buadi Francis K.,Elliott Michelle A.,Gastineau Dennis A.,Hayman Suzanne R.,Hogan William J.,Inwards David J.,Johnston Patrick B.,Kumar Shaji,Lacy Martha Q.,Leung Nelson,Micallef Ivana N.M.,Porrata Luis F.,Schafer Barbara A.,Wolf Robert C.,Litzow Mark R.

Publisher

Elsevier BV

Subject

General Medicine

Reference20 articles.

1. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age;Reece;Bone Marrow Transplant,2003

2. Standard therapy versus autologous transplantation in multiple myeloma;Attal;Hematol Oncol Clin North Am,1997

3. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol;Moreau;Blood,2006

4. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma;Mishra;Clin Lab Haematol,2003

5. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study;Mishra;Bone Marrow Transplant,2005

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials;European Journal of Cancer;2024-09

2. A scoping review of pharmacists' clinical activities and impact on the care of patients with multiple myeloma;International Journal of Clinical Pharmacy;2024-08-07

3. Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration;Frontiers in Immunology;2024-08-06

4. Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact;Frontiers in Immunology;2024-07-16

5. Optimizing autologous stem cell transplantation for multiple myeloma: early step-down ward vs. HEPA-filtered room settings – a practical approach for resource-constrained settings;2024-05-29